Lexicon Pharmaceuticals Inc (LXRX) FinancialsLXRXLexicon Pharmaceuticals Inc

Evaluating the bottom line, Lexicon Pharmaceuticals, Inc. maintains a gross margin of 94.36%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -3835.26%, while the net margin is -4591.76%. These profitability ratios, combined with a Return on Equity (ROE) of -40.21%, provide a clear picture of how effectively LXRX converts its operational activities into shareholder value.

In the context of the broader market, LXRX competes directly with industry leaders such as GYRE and ANNX. With a market capitalization of $747.53M, it holds a leading position in the sector. When comparing efficiency, LXRX's gross margin of 94.36% stands against GYRE's 92.41% and ANNX's N/A. Such benchmarking helps identify whether Lexicon Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Lexicon's gross margin remains strong at 94.36% in Q2 2026, but the company has reported significant net losses, including a net income loss of $31.77 million in the same quarter. The current ratio is high at 13.37, indicating good short-term liquidity.